Targeted therapy in advanced colon cancer: the role of new therapies.
Tabernero
J
J
Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain.
Salazar
R
R
Casado
E
E
Martinelli
E
E
Gómez
P
P
Baselga
J
J
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D009389:Neovascularization, Pathologic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000502:physiology*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D016861:Cyclooxygenase Inhibitors; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor